Recently, subgroup study data of the Chinese population have illuminated new strategies for the treatment of recurrent/refractory multiple myeloma. The results of the DREAMM-7 international multicenter study involving Chinese scholars demonstrate that an innovative therapy targeting BCMA with an antibody-drug conjugate (ADC), mAb combined with bortezomib and dexamethasone (B-Vd regimen), shows higher complete response (CR) rates and objective response rates (ORR), longer progression-free survival (PFS), and overall survival (OS) benefits compared to current standard treatments in Chinese patients with recurrent/refractory conditions. This not only provides key Chinese evidence for the global treatment of multiple myeloma but also marks another important example of China’s clinical research in multiple myeloma moving from a “follower” to a “leader”.
Multiple myeloma is the second largest malignant tumor in the hematological system. With the acceleration of aging in China, its incidence is gradually rising. “The annual incidence of multiple myeloma in China is about 1-2/100,000. Although this number is not high, due to the large population base, there are more than 17,000 new cases
